Please try another search
For the three months ended 31 March 2022, IntriCon Corporation revenues increased 4% to $33.1M. Net loss totaled $657K vs. income of $714K. Revenues reflect Medical Biotelemetry Diabetes segment increase of 11% to $20.3M, Medical Biotelemetry Other Medical segment increase of 25% to $3.7M, All other countries segment increase of 51% to $5M, Europe segment increase of 55% to $2M.
Period Ending: | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 |
---|---|---|---|---|
Total Revenue | 33.06 | 32.17 | 31.05 | 30.21 |
Gross Profit | 8.87 | 8.12 | 7.18 | 7.87 |
Operating Income | -0.43 | 0.1 | 0.48 | -0.94 |
Net Income | -0.66 | 0.02 | 0.34 | -1.18 |
Period Ending: | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 |
---|---|---|---|---|
Total Assets | 126.51 | 122.46 | 123.41 | 124.09 |
Total Liabilities | 32.9 | 28.8 | 30.63 | 32.19 |
Total Equity | 93.61 | 93.66 | 92.78 | 91.89 |
Period Ending: | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 |
---|---|---|---|---|
Period Length: | 3 Months | 0 Months | 9 Months | 6 Months |
Cash From Operating Activities | -1.66 | 0.44 | 3.2 | 1.34 |
Cash From Investing Activities | 1.63 | -2.22 | 2.49 | -3.53 |
Cash From Financing Activities | -0.31 | -1.15 | -1.23 | -0.23 |
Net Change in Cash | -0.28 | -3.05 | 4.39 | -2.54 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review